SEBIO 2005 Exhibitor Profiles.

CHARLESTON, S.C. -- The 2005 SEBIO Investor Forum takes place December 1-2 at the Charleston Place hotel in Charleston, SC. For in-depth information about the event, please visit http://www.sebioforum.org/2005.

Below are profiles from SEBIO 2005 exhibitors and sponsors; breaking news releases are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Business Wire is the official news wire service for SEBIO 2005.

Company: AtheroGenics
Ticker Symbol: AGIX
Media Contact: Donna Glasky
Investor Relations Contact: Donna Glasky
Phone: [phone]
E-mail: [e-mail]
Web: www.atherogenics.com

AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including heart disease (atherosclerosis),
rheumatoid arthritis and asthma. The Company's lead compound,
AGI-1067, is being evaluated in the pivotal Phase III clinical trial
called ARISE, as an oral therapy for the treatment of atherosclerosis.
AGI-1096 is a novel, oral agent in Phase I that is being developed for
the prevention of organ transplant rejection in collaboration with
Astellas. AtheroGenics also has preclinical programs in rheumatoid
arthritis and asthma utilizing its novel vascular protectant(R)
technology.

Company: Carilion Biomedical Institute
Media Contact: Cheryl Valentine
Phone: [phone]
Web: www.biomedicalinstitute.com

Carilion Biomedical Institute (CBI) (www.biomedicalinstitute.com) is
dedicated to improving the health and lives of people worldwide by
partnering with scientists, researchers, and the medical and business
communities to create major advances in healthcare. CBI makes
early-stage investments in promising young companies and also connects
early-stage companies to strategic real estate, management talent,
manufacturing partners and healthcare customers. Start-up biomedical
companies, entrepreneurs and inventors with a business plan or
biomedical concept that are interested in working with CBI should
contact the Carilion Biomedical Institute at 540-581-0123. CBI's
current portfolio consists of Biomedical Implant Technology, ConBrio
Systems, Elcare Innovations, Intrexon, Ocucure Therapeutics, and
Surgicaltools.com.

Company: GE Healthcare Financial Services
Media Contact: Deia Campanelli
Investor Relations Contact: Deia Campanelli
Phone: [phone]
E-mail: [e-mail]
Web: www.GEHealthcareFinance.com

GE Healthcare Financial Services' life science finance group has
partnered with more than 500 companies throughout the United States,
Canada and Europe, providing over $1.2 billion in financing to the
life science market. The team delivers innovative and flexible
financing solutions to help customers preserve their cash and
liquidity. For over a decade, it has assisted life science companies
large and small, from the first venture round to post-IPO. GE
Healthcare Financial Services is a provider of capital, financial
solutions, and related services for the global healthcare market, with
over $13 billion of capital committed to the healthcare industry.

Company: Glenveigh Pharmaceuticals
Media Contact: Kim Knoblauch, 919 Marketing, 919-557-7890
Phone: [phone]
E-mail: [e-mail]
Web: www.glenveigh.com

Glenveigh Pharmaceuticals is a specialty medical company focused on
high risk pregnancy care (maternal-fetal medicine). Its first disease
target is preeclampsia (PE). Glenveigh's lead initiative is a Phase II
study of Digibind(R) in eligible pregnant women with severe PE.
Glenveigh also has two proprietary PE diagnostic products under
development. Preeclampsia is a serious medical condition affecting
5-8% of the approximately 6.4 million pregnancies that occur annually
in the U.S. There are no effective treatments, no diagnostics, and no
cure. The annual U.S. healthcare cost of PE exceeds $7 billion.

Company: Grant Thornton LLP
Media Contact: Amy Graves
Phone: [phone]
E-mail: [e-mail]
Web: http://www.gt.com

Grant Thornton LLP is the U.S. member firm of Grant Thornton
International, a leading international organization of independently
owned and managed accounting and consulting member firms providing
assurance, tax and advisory services to businesses and their owners.
Through member firms in more than 100 countries, including 50 offices
in the United States, the partners of Grant Thornton member firms
provide personalized attention and the highest quality service to
public and private biotechnology clients around the globe.

Company: NanoScreen, LLC
Media Contact: Noelle Webb
Investor Relations Contact: Noelle Webb
Phone: [phone]
E-mail: [e-mail]
Web: www.NanoScreen.com

NanoScreen, LLC, is a manufacturing company specializing in the
production of consumable pharmaceutical supplies used in
pharmaceutical research. In addition, the company also focuses on
building, repairing and refurbishing the automated pipetting equipment
used in pharmaceutical research. NanoScreen's premier product line
includes the world's smallest disposable pipette, used for
distributing extremely small amounts of liquid very accurately
(nanoliters). It is compatible with the world's first 1,536 channel
air displacement syringe head, which consist of 1,536 micro-syringes
in an area of just 3.5 inches by 5 inches (72mm x 108mm).

Company: ParinGenix
Media Contact: Eric Leire, MD, CEO
Phone: [phone]
Email: [e-mail]
Web: www.paringenix.com (coming soon)

ParinGenix is a clinical-stage pharmaceutical company developing 2-O,
3-O desulfated heparin (ODSH) as an anti-inflammatory drug for
respiratory indications. ParinGenix chemically modifies heparin to
retain anti-inflammatory activity and to reduce anticoagulation
properties (less than 3% of anticoagulant activity of unfractionated
heparin while retaining 95% of anti-inflammatory activity). ParinGenix
develops two ODSH products: PGX-100: intravenous dosage form to treat
acute exacerbations of COPD. ParinGenix completed Phase I with no
reported adverse events. PGX-200: aerosolized dosage form to treat
exacerbations of cystic fibrosis, asthma and COPD. ParinGenix received
Orphan Drug designation for PGX-200 in cystic fibrosis.

Company: Pathfinder Therapeutics, Inc.
Media Contact: Craig Staples
Investor Relations Contact: Jim Stefansic
Phone: [phone]
E-mail: [e-mail]
Web: http://www.pathfindertherapeutics.com

Pathfinder Therapeutics Inc. (PTI), a medical device corporation
located in Nashville, is developing an image-guided therapy system for
open liver surgery, an industry with a potential revenue stream of
over $1.50 billion. Currently, there are no image-guided liver surgery
(IGLS) systems on the market that actively use preoperative medical
images to guide tumor resections or ablations. Building on 15 years of
surgical guidance R&D in academic settings, the founders of PTI
developed a prototype IGLS system. First in man experiments have
already been performed, and a clinical prototype will be completed and
ready for FDA 510(k) evaluation by early 2006.

Company: SC Department of Commerce
Media Contact: Karen Owens
Phone: [phone]
E-mail: [e-mail]
Web: www.SCCommerce.com

A confluence of medical, marine, industrial and agricultural sciences
puts South Carolina at the forefront of research and discovery. With
an internationally recognized pro-business climate, plus a proven
commitment to support the biotech industry, your company can go from
idea to implementation quickly and efficiently. Some of our partners
in discovery: Medical University of South Carolina, University of
South Carolina, Clemson University, Savannah River National
Laboratory, Greenwood Genetics Center, Hollings Marine Laboratory, SC
Biotechnology Incubation Facility, and SC Research Authority.
Sponsors: SC Department of Commerce, Charleston Regional Development
Alliance, Aiken-Edgefield Economic Development Partnership, Santee
Cooper, Central SC Alliance and SCBIO.

Company: South Carolina Research Authority
Media Contact: Dave McNamara
Investor Relations Contact: Dave McNamara
Phone: [phone]
E-mail: [e-mail]
Web: www.scra.org

SCRA Innovation Centers - SCRA is investing $12M to form and support
three innovation centers across the state, by joint venture with
Clemson, MUSC, USC and community partners. Innovation Center clients
will license or utilize the universities' intellectual property and
work in close collaboration with faculty to apply and commercialize
research to produce new products and services. Through the Innovation
Centers, SCRA will provide a brace of support to new entities, ranging
from startups to research "landing party" teams from large
corporations, including facilities, business plan screening, seed
capital, coaching and mentoring, and communication with customers,
stakeholders, and the public.

Company: The South Carolina Technology Alliance
Media Contact: Mrs. Carole Wilson
Phone: [phone]
E-mail: [e-mail]
Web: www.sctech.org

South Carolina will prosper in the 21st century as a recognized leader
in attracting, creating, growing and retaining world-class technology
intensive companies while preserving our excellent quality of life,
strong work ethic and exceptional business environment. The South
Carolina Technology Alliance is a non-profit / private public
non-partisan technology orientated Think Tank that develops and
advances visionary economic development policies by providing
opportunities to collaborate among a diverse cross-section of our
states business, academic and legislative leaders and our states
economic and community development sectors, as well as identifying and
developing technology workforce skills, working to create investment
capital for our entrepreneurial knowledge base technology companies.
Funding for our Alliance comes from local, state government,
technology entrepreneurs, various grants and from services provided to
our allies across the state. We provide our members with authoritative
research, entrepreneurial discussions groups, as well as our annual
technology legislative agenda, and other pilot projects in the areas
of technology and innovation, workforce development, community
technology development, civic engagement and leadership "Creating
South Carolina's Future Through Technology Leadership."

Company: Square 1 Bank
Media Contact: Denise Gutschmit, 919-314-3073
Phone: [phone]
E-mail: [e-mail]
Web: www.square1bank.com

Square 1 Bank provides financial services to venture capital firms and
companies that receive venture capital investment. Our expertise,
focus and strong capital base provide a firm foundation to support our
clients through all stages of growth. Square 1 provides unique,
tailored products and solutions. From the latest in technology-based
convenience to a banker you'll know as a friend, Square 1 believes
that a banking relationship should be anticipatory, responsive and
active. Square 1 Bank has offices in seven locations: Boston, Austin,
Seattle, San Diego, Palo Alto, Reston and our national service hub in
Durham, North Carolina.

Company: Sutherland Asbill & Brennan LLP
Media Contact: Caroline Clouse
Phone: [phone]
E-mail: [e-mail]
Web: www.sablaw.com

Sutherland Asbill & Brennan LLP is a national law firm whose clients
include basic research academicians, bio-entrepreneurs and
multinational companies. Sutherland's life sciences lawyers use a
multi-disciplinary approach to help clients protect and leverage their
intellectual property, structure their businesses, raise capital, hire
and compensate officers and other key employees, comply with federal,
state and international regulations, and deal with most other legal
challenges. Many of our attorneys have graduate degrees in the life
sciences to better understand our clients, while others have a more
commercial, business-oriented background, with connections to funding
sources such as angel investors, venture capital companies and
investment banks.

Company: Wyrick Robbins Yates & Ponton LLP
Media Contact: MaryLou Rothfuss, Marketing Coordinator
Investor Relations Contact: Kenneth E. Eheman, Esq.
Phone: [phone]
E-mail: [e-mail]
Web: www.wyrick.com

Wyrick Robbins Yates & Ponton LLP, the region's leading law firm in
the representation of life sciences companies, is proud to sponsor
SEBIO 2005. Wyrick Robbins has spent over 25 years helping life
sciences companies navigate the complexities of financings, clinical
trials, and strategic collaborations as these globally active life
science companies achieve market success and improve the quality of
human life. Wyrick Robbins is located in Raleigh, North Carolina, a
part of the Research Triangle Park community.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email [e-mail].